Real-world treatment study for relapsed or refractory myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple myeloma that matches standard diagnostic rules (IMWG).
- Your energy/ability to do daily activities is limited but not severely (ECOG 0–1, or 0–2 if starting talquetamab).
- You are able to take part without becoming pregnant during the study, and you must agree to pregnancy prevention rules if applicable.
- If you join, you must sign a consent form and understand the study is observational (it mainly observes real care).
- If you join Period 1 or 2: you have had at least 3 prior treatment lines and your disease has progressed after the most recent one.
- If you join Period 1 or 2: you must have “measurable” disease on blood or urine tests (or in some cases, specific abnormal blood light-chain results).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LBL-034 in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
This trial tests a combination of two drugs, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination works better than using one drug alone.
This study looks at how patients with multiple myeloma are doing after receiving the drugs teclistamab or talquetamab in regular medical care (not in a clinical trial). It helps doctors understand real-world outcomes and side effects.
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.